Posaconazole indications and usage: Difference between revisions
Jump to navigation
Jump to search
Ahmed Zaghw (talk | contribs) (Created page with "__NOTOC__ {{Posaconazole}} {{CMG}}; {{AE}} {{AZ}} ==Indications And Usage== ===Prophylaxis of Invasive Aspergillus and Candida Infections=== Noxafil® delayed-release table...") |
Ahmed Zaghw (talk | contribs) No edit summary |
||
| Line 9: | Line 9: | ||
Noxafil® delayed-release tablets and oral suspension are indicated for: | Noxafil® delayed-release tablets and oral suspension are indicated for: | ||
*: | *:Prophylaxis of invasive [[Aspergillus]] | ||
*:[[Candida]] infections in patients | *:Prophylaxis of [[Candida]] infections | ||
*13 years of age and older | in patients with | ||
*High risk of developing these infections | |||
*Severely immunocompromised, such as hematopoietic stem cell transplant (HSCT) recipients with [[graft-versus-host disease]] (GVHD) or those with hematologic malignancies with prolonged neutropenia from chemotherapy. | ::*13 years of age and older | ||
::*High risk of developing these infections | |||
::*Severely immunocompromised, such as hematopoietic stem cell transplant (HSCT) recipients with [[graft-versus-host disease]] (GVHD) or those with hematologic malignancies with prolonged neutropenia from chemotherapy. | |||
===Treatment of Oropharyngeal Candidiasis Including Oropharyngeal Candidiasis Refractory to Itraconazole and/or Fluconazole=== | ===Treatment of Oropharyngeal Candidiasis Including Oropharyngeal Candidiasis Refractory to Itraconazole and/or Fluconazole=== | ||
Latest revision as of 04:45, 9 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]
Indications And Usage
Prophylaxis of Invasive Aspergillus and Candida Infections
Noxafil® delayed-release tablets and oral suspension are indicated for:
- Prophylaxis of invasive Aspergillus
- Prophylaxis of Candida infections
in patients with
- 13 years of age and older
- High risk of developing these infections
- Severely immunocompromised, such as hematopoietic stem cell transplant (HSCT) recipients with graft-versus-host disease (GVHD) or those with hematologic malignancies with prolonged neutropenia from chemotherapy.
Treatment of Oropharyngeal Candidiasis Including Oropharyngeal Candidiasis Refractory to Itraconazole and/or Fluconazole
Noxafil oral suspension is indicated for the treatment of oropharyngeal candidiasis, including oropharyngeal candidiasis refractory to itraconazole and/or fluconazole.[1]
References
Adapted from the FDA Package Insert.